{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:09:11Z","timestamp":1778058551928,"version":"3.51.4"},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"45","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,7,23]]},"DOI":"10.18632\/oncotarget.27047","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T14:22:23Z","timestamp":1563891743000},"page":"4616-4629","source":"Crossref","is-referenced-by-count":12,"title":["Oncologist uptake of comprehensive genomic profile guided targeted therapy"],"prefix":"10.18632","volume":"10","author":[{"given":"Mary K.","family":"Nesline","sequence":"first","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"DePietro","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace K.","family":"Dy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Early","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Papanicolau-Sengos","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Conroy","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"},{"name":"Center for Personalized Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia L.","family":"Lenzo","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean T.","family":"Glenn","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Grand\u2019Maison","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Edge","sequence":"additional","affiliation":[{"name":"Department of Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Akers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Opyrchal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurkamal","family":"Chatta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Frederick","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Lele","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gardner","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Morrison","sequence":"additional","affiliation":[{"name":"OmniSeq Inc., Buffalo, NY 14203, USA"},{"name":"Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"},{"name":"Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms a meta-Analysis","volume":"2","author":"Kurzrock","year":"2016","journal-title":"JAMA Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials","volume":"33","author":"Kurzrock","year":"2015","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"djv253","DOI":"10.1093\/jnci\/djv253","article-title":"Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval","volume":"107","author":"Kurzrock","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"4","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1097\/JTO.0000000000000665","article-title":"Clinical Implications of Variant ALK FISH Rearrangement Patterns","volume":"10","author":"Oxnard","year":"2015","journal-title":"J Thorac Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-12679-8","article-title":"Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches","volume":"7","author":"Pujol","year":"2017","journal-title":"Sci Rep"},{"key":"6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy","volume":"22","author":"Jones","year":"2017","journal-title":"Oncologist"},{"key":"7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1634\/theoncologist.2017-0493","article-title":"Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing","volume":"23","author":"Ross","year":"2018","journal-title":"Oncologist"},{"key":"8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Mozzillo","year":"2012","journal-title":"J Transl Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Riely","year":"2011","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1634\/theoncologist.2009-0233","article-title":"Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery","volume":"15","author":"Ilyas","year":"2010","journal-title":"Oncologist"},{"key":"11","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Colon Cancer, Version 4.2018. Fort Washington, Pennsylvania: National Comprehensive Cancer Network; 2018. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E\u2013Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study","volume":"37","author":"Ciardiello","year":"2019","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Kurzrock","year":"2012","journal-title":"Clin Cancer Res"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00002","article-title":"Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study","volume":"2017","author":"Kee","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Clarke","year":"2016","journal-title":"Genome Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"41806","DOI":"10.18632\/oncotarget.16018","article-title":"A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory","volume":"8","author":"Horombe","year":"2017","journal-title":"Oncotarget"},{"key":"17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies","volume":"7","author":"Johnsen","year":"2017","journal-title":"Cancer Discov"},{"key":"18","doi-asserted-by":"publisher","first-page":"20099","DOI":"10.18632\/oncotarget.4040","article-title":"Clinical next generation sequencing to identify actionable aberrations in a phase I program","volume":"6","author":"Janku","year":"2015","journal-title":"Oncotarget"},{"key":"19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12885-017-3587-8","article-title":"Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy","volume":"17","author":"Hosein","year":"2017","journal-title":"BMC Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1093\/annonc\/mdx294","article-title":"Oncologist use and perception of large panel next-generation tumor sequencing","volume":"28","author":"Dickler","year":"2017","journal-title":"Ann Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"20282","DOI":"10.18632\/oncotarget.24757","article-title":"The clinical impact of using complex molecular profiling strategies in routine oncology practice","volume":"9","author":"Kathan","year":"2018","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1634\/theoncologist.2015-0097","article-title":"Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center","volume":"20","author":"Schwartz","year":"2015","journal-title":"Oncologist"},{"key":"23","doi-asserted-by":"publisher","first-page":"57845","DOI":"10.18632\/oncotarget.18471","article-title":"Implementation and utilization of the molecular tumor board to guide precision medicine","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"publisher","first-page":"27145","DOI":"10.18632\/oncotarget.16057","article-title":"Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery","volume":"8","author":"Oliver","year":"2017","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"publisher","first-page":"56491","DOI":"10.18632\/oncotarget.10606","article-title":"Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers","volume":"7","author":"Rushing","year":"2016","journal-title":"Oncotarget"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.16.00046","article-title":"Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board","author":"Pratilas","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"27","unstructured":"U.S. Food and Drug Administration. CDRH\u2019s Approach to Tumor Profiling Next Generation Sequencing Tests. Silver Spring, MD: U.S. Food and Drug Administration; 2017. Available from: https:\/\/www.fda.gov\/downloads\/MedicalDevices\/ProductsandMedicalProcedures\/InVitroDiagnostics\/UCM584603.pdf."},{"key":"28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Satouchi","year":"2019","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2015.62.1854","article-title":"Modernizing Eligibility Criteria for Molecularly Driven Trials","volume":"33","author":"Schilsky","year":"2015","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"djv324","DOI":"10.1093\/jnci\/djv324","article-title":"Predicting Low Accrual in the National Cancer Institute\u2019s Cooperative Group Clinical Trials","volume":"108","author":"Veenstra","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Biesecker","year":"2013","journal-title":"Genet Med"},{"key":"32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol","volume":"31","author":"Brennan","year":"2013","journal-title":"Nature Publishing Group"},{"key":"33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Schram","year":"2017","journal-title":"Nat Med"},{"key":"34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neo.2015.03.004","article-title":"Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors","volume":"17","author":"Manivannan","year":"2015","journal-title":"Neoplasia"},{"key":"35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial","volume":"19","author":"Krishnamurthy","year":"2017","journal-title":"J Mol Diagn"},{"key":"36","first-page":"S698","article-title":"DNA Extraction of Lung Cancer Samples for Advanced Diagnostic Testing","volume":"10","author":"Papanicolau-Sengos","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T13:55:06Z","timestamp":1591451706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":36,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2019,7,23]]}},"alternative-id":["27047","31384390"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27047","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]}}}